Skip to main content

Drug Interactions between Lazcluze and olutasidenib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

olutasidenib lazertinib

Applies to: olutasidenib and Lazcluze (lazertinib)

MONITOR: Coadministration with weak inducers of CYP450 3A4 may reduce the plasma levels and effects of lazertinib, which is primarily metabolized by the isoenzyme. In a phase 1 study of healthy adult participants, concomitant use of the strong CYP450 3A4 inducer rifampin reduced the peak plasma concentration (Cmax) and systemic exposure (AUC) of lazertinib by 72% and 83%, respectively. Likewise, a pharmacokinetic model predicted that concomitant use with the moderate CYP450 3A4 inducer efavirenz would decrease lazertinib's steady state Cmax and AUC by at least 32% and 44%, respectively. Clinical data with less potent CYP450 3A4 inducers are not available.

MANAGEMENT: The potential for diminished pharmacologic effects of lazertinib should be considered if coadministration with a weak CYP450 3A4 inducer is clinically necessary. An alternative concomitant medication with no potential to induce CYP450 3A4 may be required.

References (2)
  1. (2024) "Product Information. Lazcluze (lazertinib)." Janssen Biotech, Inc.
  2. Janssen Research & Development, LLC (2024) A study to assess the effects of itraconazole and rifampin on lazertinib in healthy adult participants. https://clinicaltrials.gov/study/NCT04410094?tab=table

Drug and food interactions

Moderate

olutasidenib food

Applies to: olutasidenib

ADJUST DOSING INTERVAL: Coadministration with a high-fat meal may increase the plasma concentrations of olutasidenib. According to the product labeling, administration of a single 150 mg dose with a high-fat meal (approximately 800 to 1000 calories, with approximately 50% of those calories from fat) increased olutasidenib peak plasma concentration (Cmax) and systemic exposure (AUC) by 191% and 83%, respectively, in healthy subjects.

MANAGEMENT: Olutasidenib should be administered at about the same time each day, on an empty stomach at least 1 hour before or 2 hours after a meal.

References (1)
  1. (2022) "Product Information. Rezlidhia (olutasidenib)." Rigel Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer